Cargando…

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial

Detalles Bibliográficos
Autores principales:	de Souza, MS, Trichavaroj, R, Schuetz, A, Chuenarom, W, Phuang-ngem, Y, Jongrakthaitae, S, Ratto-Kim, S, Nitayaphan, S, Dally, L, Rerks-Ngam, S, Tartaglia, J, Francis, D, Michael, NL, Paris, RM, Kim, JH
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767576/ http://dx.doi.org/10.1186/1742-4690-6-S3-O52

Ejemplares similares

Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2011)

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial
por: Kim, JH, et al.
Publicado: (2009)

ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone
por: Costanzo, Margaret C., et al.
Publicado: (2023)

Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E
por: Ratto-Kim, Silvia, et al.
Publicado: (2015)

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
por: Zolla-Pazner, Susan, et al.
Publicado: (2013)

Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates
por: Herrera, Carolina, et al.
Publicado: (2022)

P15-14. Assuring data quality of the phase III vaccine trial of ALVAC vaccine priming and AIDSVAX vaccine boosting in Thailand
por: Kaewkungwal, J, et al.
Publicado: (2009)

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene
por: O'Connell, RJ, et al.
Publicado: (2012)

Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate
por: Vaccari, Monica, et al.
Publicado: (2019)

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults
por: Gray, Glenda E, et al.
Publicado: (2021)

The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy)
por: Angel, Jonathan B., et al.
Publicado: (2015)

ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2019)

P19-51 LB. Improvement of the efficacy of ALVAC-HIV vaccine candidates for humans in non human primates
por: Franchini, G
Publicado: (2009)

Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2020)

A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells
por: Eller, Michael A., et al.
Publicado: (2011)

The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination
por: Tomalka, Jeffrey Alan, et al.
Publicado: (2021)

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
por: Moodie, Zoe, et al.
Publicado: (2020)

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
por: Laher, Fatima, et al.
Publicado: (2020)

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection
por: Auclair, Sarah, et al.
Publicado: (2018)

1521 Missed Opportunities for HIV prevention at an Integrated Hospital System in Bronx, NY
por: Liggett, Alisha, et al.
Publicado: (2014)

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
por: Easterhoff, David, et al.
Publicado: (2020)

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
por: Bekker, Linda-Gail, et al.
Publicado: (2018)

1521 : la Conquista de México en el arte /
Publicado: (2020)

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family
por: Bonsignori, M, et al.
Publicado: (2012)

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2015)

An HIV Vaccine for South-East Asia—Opportunities and Challenges
por: Pitisuttithum, Punnee, et al.
Publicado: (2013)

1521. High frequency of vitamin D deficiency in hospitalized patients with HIV: A prospective study in Colombia
por: Ortiz-Martínez, Yeimer, et al.
Publicado: (2023)

The discovery and conquest of Mexico1517 -1521
por: Díaz del Castillo, Bernal, 1496-1584
Publicado: (1956)

The discovery and conquest of Mexico, 1517-1521 /
por: Díaz del Castillo, Bernal, 1496-1584
Publicado: (1996)

1521 en el arte barroco /
por: Arroyo Lemus, Elsa Minerva
Publicado: (2021)

Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial
por: Gombe, Ben, et al.
Publicado: (2022)

Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation
por: Schuetz, Alexandra, et al.
Publicado: (2014)

Ecos de 1521 : portentos y presagios en las conquistas de América /
por: Pérez Gerardo, Diana Roselly
Publicado: (2021)

Impact of HIV vaccination on laboratory diagnosis: case reports
por: Suthon, Vongsheree, et al.
Publicado: (2002)

México en dos tiempos: 1521- 1821
por: Ayala Flores, Hubonor, et al.
Publicado: (2022)

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
por: Fourati, Slim, et al.
Publicado: (2019)

The Canarypox-virus vaccine vector ALVAC triggers the release of IFN-γ by Natural Killer (NK) cells enhancing Th1 polarization
por: Ryan, Elizabeth J., et al.
Publicado: (2007)

Tres siglos de economía novohispana, 1521-1821 /
por: Blanco, Mónica
Publicado: (2000)

AIDS Vaccine for Asia Network (AVAN): Expanding the Regional Role in Developing HIV Vaccines
por: Kent, Stephen J., et al.
Publicado: (2010)

Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells
por: Harenberg, Anke, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_cd2r0h1chglpdr7nu6b8po91kg